Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03763929 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
A Phase 2 study, sponsored by Diffusion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03763929: Clinical Trial Phase 2 study, sponsored by Diffusion Pharmaceuticals.
NCT03763929 is a Phase 2 study that was terminated before completion, run by Diffusion Pharmaceuticals. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03763929, a Phase 2 study, was terminated before completion, sponsored by Diffusion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.
Primary Outcome
Modified Rankin Scale (mRS) is a measure of global disability. Total scale range is 0-6, with lower values indicating better outcomes. 0 = No symptoms at all 1. = No significant disability despite symptoms; able to carry out all usual duties and activities 2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. = Moderate disability; requiring some help, but able to walk without assistance 4. = Moderately severe disability;
Interventions
- OTHER Placebo
- DRUG Trans-Sodium Crocetinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2020-10-19 |
| Phase | Phase 2 |
Why NCT03763929 stopped before completion
NCT03763929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03763929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03763929 about?
NCT03763929 is a clinical study titled "Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke". This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.
What is the current status of trial NCT03763929?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-08-22. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT03763929?
The interventions under investigation include: Placebo (OTHER), Trans-Sodium Crocetinate (DRUG).
Who is sponsoring clinical trial NCT03763929?
This trial is sponsored by Diffusion Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03763929's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI